Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3
This phase 2 study was designed to assess the safety and efficacy of masitinib (AB1010) in patients with relapsing/refractory t(4;14) Multiple Myeloma. Response and progression were assessed according to the Bladé revised IMWG criteria1 from lowest point.
Multiple Myeloma
DRUG: masitinib (AB1010)
Tumor Response Rate, based on the criteria published by Blade and on the criteria SWOG, 16 weeks
Tumor response rate with AB1010 plus dexamethasone, 16 weeks|Time to tumor progression and duration of response in responder patients, 16 weeks
This phase 2 study was designed to assess the safety and efficacy of masitinib (AB1010) in patients with relapsing/refractory t(4;14) Multiple Myeloma. Response and progression were assessed according to the Bladé revised IMWG criteria1 from lowest point.